Mark Stein

11PUBLICATIONS

167CO-AUTHORS

Molecular targetsCancer geneticsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (11)

Sort by Publication Date:

|May 18, 2026

Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|Feb 26, 2026

Trial Design and Objectives for Patients With Prostate Cancer: Recommendations From the Prostate Cancer Working Group 4.

Andrew J Armstrong, Michael J Morris, Wassim Abida

|Jun 12, 2025

Diabetes and Acute Care Use Among Patients With Metastatic Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors.

Michael A Liu, Rohit Raghunathan, Karie Runcie

|Jun 01, 2025

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.

Mark N Stein, Armelle Vinceneux, Debbie Robbrecht

|Feb 24, 2025

Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.

Miya B Hugaboom, Lena V Wirth, Kelly Street

|Jan 23, 2025

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas.

Jason J Luke, Randy F Sweis, J Randolph Hecht

Pageof 2

Frequent Collaborators

Naomi Balzer-Haas

Opeyemi A Jegede

David Braun

Thomas Denize

David F McDermott

Sabina Signoretti

Michael B Atkins

Toni K Choueiri

Sayed Matar

Varunika Savla

Frequent Collaborators

Naomi Balzer-Haas

Opeyemi A Jegede

David Braun

Thomas Denize